Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients )

Trial Profile

Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients )

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms APERCU
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 Jun 2016 Status changed from active, no longer recruiting to recruiting.
    • 02 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top